Publications by authors named "G Biti"
Article Synopsis
- The study aimed to survey Sicilian radiation oncology centers affiliated with AIRO to understand how radio-chemotherapy is integrated in both neoadjuvant and adjuvant settings, along with assessing surgical procedures and treatment toxicity.
- A questionnaire was distributed in late 2017 to gather data from 13 of the 17 radiation oncology centers in Sicily, covering treatment methodologies and outcomes from 2012 to 2016, which represented about 85% of the Sicilian population.
- Results showed that 784 patients were treated, primarily during the neoadjuvant phase (62%), with a median age of 67 years; most received single-agent chemotherapy combined with radiotherapy, while some faced cardiovascular issues, leading to 25
Background: Oral mucositis is a side effect of treatment regimens containing 5-fluorouracil (5-FU). The purpose of this study was to present our evaluation to see if rosiglitazone (RGZ) protected normal tissues from chemotherapy-induced oral mucositis.
Methods: C57BL/6J mice were treated with 5-FU for 5 days, with or without RGZ.
A PPAR-gamma agonist protects from radiation-induced intestinal toxicity.
United European Gastroenterol J
March 2017
Objective: Because of its anti-inflammatory, anti-fibrotic, anti-apoptotic and anti-neoplastic properties, the PPAR-γ agonist rosiglitazone is an interesting drug for investigating for use in the prevention and treatment of radiation-induced intestinal damage. We aimed to evaluate the radioprotective effect of rosiglitazone in a murine model of acute intestinal damage, assessing whether radioprotection is selective for normal tissues or also occurs in tumour cells.
Methods: Mice were total-body irradiated (12 Gy), with or without rosiglitazone (5 mg/kg/day).
Background: Due to its anti-inflammatory, antifibrotic and antineoplastic properties, the PPAR gamma agonist rosiglitazone is of interest in prevention and therapy of radiation-induced toxicities. We aimed to evaluate the radioprotective effect of rosiglitazone in a mouse model of radiation-induced oral mucositis.
Material And Methods: Oral mucositis was obtained by irradiation of the oral region of C57BL/6J mice, pretreated or not with rosiglitazone.
Purpose/objective(s): Due to its anti-inflammatory, antifibrotic and antineoplastic properties, the PPAR-γ agonist rosiglitazone is of interest in the prevention and therapy of radiation-induced pulmonary injury. We evaluated the radioprotective effects of rosiglitazone in a murine model of pulmonary damage to determine whether radioprotection was selective for normal and tumor tissues.
Methods: Lungs in C57BL/6J mice were irradiated (19 Gy) with or without rosiglitazone (RGZ, 5mg/kg/day for 16 weeks, oral gavage).